Bepotastine

INTRODUCTION

Indications

Treatment of itching associated with allergic conjunctivitis.

Action

Acts as a histamine H₁ receptor antagonist; also inhibits the release of histamine from mast cells; does not bind to or inactivate histamine. Therapeutic Effects: Decreased ocular itching associated with allergic conjunctivitis.

Adverse Reactions/Side Effects

CNS: headache. EENT: nasopharyngitis. GI: taste in mouth following instillation.

PHYSICAL THERAPY IMPLICATIONS

Examination and Evaluation

• Monitor eye pain, itching, and inflammation to help document whether drug therapy is successful in resolving allergic conjunctivitis.

Patient/Client-Related Instruction

• Check that the patient and family or caregivers understand ophthalmic application procedures and adhere to the recommended dosing schedule.

• Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged headache, altered taste, or inflammation of the nose and pharynx.

Pharmacokinetics

Absorption: Some systemic absorption follows ophthalmic administration.

Distribution: Unknown

Metabolism and Excretion: Minimally metabolized by the liver; 75–90% excreted unchanged in urine

Half-life: Unknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity.

Use Cautiously in: Contact lens use OB: Use during pregnancy if potential maternal benefit justifies the potential risk to fetus; Lactation: Use cautiously during breastfeeding; Pedi: Safe and effective use in children <2 yr has not been established.

Interactions

Drug-Drug: None noted

Route/Dosage

Ophthalmic (Adults): 1 drop in affected eye(s) twice daily.

Availability

Ophthalmic solution: 1.5%